Permanent URL to this publication: http://dx.doi.org/10.5167/uzh-57564
Denton, C P; Avouac, J; Behrens, F; Furst, D E; Foeldvari, I; Humbert, M; Huscher, D; Kowal-Bielecka, O; Matucci-Cerinic, M; Nash, P; Opitz, C F; Pittrow, D; Rubin, L J; Seibold, J R; Distler, O (2011). Systemic sclerosis-associated pulmonary hypertension: why disease-specific composite endpoints are needed. Arthritis Research & Therapy, 13(3):114.
View at publisher
Pulmonary arterial hypertension (PAH) is a serious complication of systemic sclerosis (SSc). In clinical trials PAH-SSc has been grouped with other forms, including idiopathic PAH. The primary endpoint for most pivotal studies was improvement in exercise capacity. However, composite clinical endpoints that better reflect long-term outcome may be more meaningful. We discuss potential endpoints and consider why the same measures may not be appropriate for both idiopathic PAH and PAH-SSc due to inherent differences in clinical outcome and management strategies of these two forms of PAH. Failure to take this into account may compromise progress in managing PAH in SSc.
26 downloads since deposited on 29 Jan 2012
7 downloads since 12 months
|Item Type:||Journal Article, not refereed, further contribution|
|Communities & Collections:||04 Faculty of Medicine > University Hospital Zurich > Rheumatology Clinic and Institute of Physical Medicine|
|Dewey Decimal Classification:||610 Medicine & health|
|Deposited On:||29 Jan 2012 17:05|
|Last Modified:||05 Apr 2016 15:31|
Users (please log in): suggest update or correction for this item
Repository Staff Only: item control page